You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Exacerbations* in COPD: What’s the risk?

Of COPD patients who exacerbated in the previous year, >40% will experience a moderate/severe exacerbation over 12 months on dual maintenance therapy.** 1

The consequences of COPD exacerbations can be significant for your patients and beyond.

COPD Quality of Life

Decreased health-related quality of life 3

COPD Exacerbations

Most common reason for COPD-related hospitalisation 4

COPD Exacerbations

Hospitalisation is associated with increased risk of mortality 5

COPD Exacerbations

Major contributor to the economic burden 5 6 7

COPD Exacerbations

2x increased risk of myocardial infarction 1-5 days after ††8

The strongest predictor of future exacerbation risk in patients with COPD, is a prior history of exacerbations 9.

Watch the video to find out what you can do for patients who are symptomatic and at risk of an exacerbation*

Take action against exacerbation risk.

Making sure your patients who are symptomatic and at risk of an exacerbation* are on the optimal treatment is important to help reduce future exacerbations. The resources below are available to support your management of patients with COPD.

COPD assessment test

Access the COPD assessment test to identify your at-risk patients.

Click Here

Patient with COPD

Could your COPD patients benefit from a single inhaler triple therapy to reduce exacerbation risk?

Learn more here >

*Defined as a worsening of symptoms, or has experienced an exacerbation treated with antibiotics or oral corticosteroid in the past 12 months

**Based on a 52-week, randomised, double-blind, non-inferiority trial comparing indacaterol/glycopyrronium (110/50 μg) once daily to fluticasone propionate/salmeterol (500/50 μg) twice daily in COPD patients with a history of at least one exacerbation in the previous year (for which they received treatment with systemic glucocorticoids, antibiotic agents, or both). IND/GLY showed non-inferiority and superiority to FP/SAL in reducing the annual rate of all COPD exacerbations.
LAMA/LABAs are indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.

Post hoc analysis of the 3-year Toward a Revolution in COPD Health (TORCH ) study in patients with moderate or severe COPD (treatment arms: salmeterol 50 mcg, fluticasone propionate 500 mcg, salmeterol /fluticasone propionate 50 /500 mcg or placebo, all twice daily ). The primary endpoint of the study did not reach statistical significance. Data shown compares patients with 0-1 moderate /severe exacerbations per annum vs. 0 exacerbations per annum. Analysis includes patients on active treatment and placebo.

††2.27-fold (95% CI, 1.1-4.7; P=0.03) increased risk of MI 1 to 5 days after exacerbation (defined by prescription of both steroids and antibiotics).

References:

  1. Wedzicha J, et al N Engl J Med 2016; 374:2222-2234.
  2. Celli B et al. Am J Respir Crit Care Med 2008; 178:332-338
  3. Seemungal TA et al. Am J Respir Crit Care Med 1998; 157:1418-1422.
  4. Mapel DW, Robers MH. Pharmacoeconomics 2012; 30:869-885.
  5. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obtructive Pulmonary Disease (GOLD), 2020. Available at www.goldcopd.org. Accessed July 2020.
  6. Pasquale MK et al. Int J COPD 2012; 7:757-764.
  7. Yu AP et al. J Med Econ 2011; 14:315-323.
  8. Donaldson GC et al. Chest 2010; 137:1091-1097)
  9. Hurst JR, Vestbo J, Anzueto A, et al. N Engl J Med. 2010;363(12):1128-1138.


TRELEGY Ellipta was created in collaboration with

Innoviva

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.